TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’? - Wikidata - wikimedia - TriplyDB

TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?

TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?

http://www.wikidata.org/entity/Q57697170

about

Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain Concepts of 'personalization' in personalized medicine: implications for economic evaluation.Cost-effectiveness analysis in pharmacogenomics.Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs.A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study.The economic case for precision medicine.

P2860

Q34326911-4A052A75-1B02-49D7-8445-4E2A246B9417 Q35575935-1DA5920C-883C-44D5-A038-4348DEEF5122 Q37736459-317F37BF-2544-47B7-9002-EDD5B9C77726 Q45928693-893D878A-22D8-42B5-B83E-A5D0A3A17DE0 Q50518269-A970862A-1FE3-4F6A-ACD1-C349B69DEFEE Q55217201-271816AF-8231-431D-8D1E-06BA666F2C98

P2860

TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?

http://www.wikidata.org/entity/Q57697170

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2009

@uk

name

TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?

@en

TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?

@nl

type

label

TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?

@en

TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?

@nl

prefLabel

TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?

@en

TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’?

@nl

P1433

Q57697170-98F66A13-5F9B-4326-99F3-A1CE87D371C3

P1476

Q57697170-83C7E327-657D-405E-9A75-4ADB951F78ED

P2093

Q57697170-2BD0E715-CCCB-460C-8213-A662B16BB089

Q57697170-5A58B2E9-4725-41CC-8BC1-3DE3A1EFD5BD

Q57697170-A5018679-DBE5-4F0F-8796-2CEF0AD71A7C

P2860

Q57697170-0DF93706-8E91-4987-B23D-9157E4540F81

Q57697170-23047225-8AD1-4DCF-B59C-AF8E7234927C

Q57697170-466945BA-C63F-4F46-A7EA-8B5278A83877

Q57697170-46DA15F4-7AA3-4088-89CF-C214CD1A0D10

Q57697170-5A64F86F-0DA4-4BB9-8B6E-B9EEBD428099

Q57697170-7190F7D6-1973-41C0-BBF6-1531C834749B

Q57697170-7BE4C0E5-2D37-4FA6-AD41-732FF487A226

Q57697170-7FC10939-9639-496A-A1E2-9674D33FDC32

Q57697170-86631DDE-6D97-477B-9DFE-ECB8716DDE07

Q57697170-89DE1F86-28CE-486F-A5C4-E62D1B912F9E

P304

Q57697170-8B67DDAF-B95E-4727-BCEF-A308F81BB4CE

P31

Q57697170-ECAA37DD-702B-4AFF-92FE-F262203124E6

P356

Q57697170-921B1708-3ED7-4752-8377-CE744B704722

P407

Q57697170-89E0B516-8985-4C68-8718-B64792FAE96D

P433

Q57697170-2E0D0FB5-5E2F-4894-B559-DE2CBCACD8C5

P478

Q57697170-FA467C31-1828-4C39-95F2-F9CB52000D45

P50

Q57697170-64FAF0E5-5EB4-4B4D-B68B-28EE4F7D57A0

Q57697170-D2D8C95A-55BC-465A-927F-22A22342D443

P577

Q57697170-6E067177-067B-4E95-858D-7372437E5657

P698

Q57697170-C575810E-0A60-4B11-8182-5BE7B4831E67

P356

17410541.6.1.103

P1433

Personalized Medicine

P1476

TPMT testing in azathioprine: a 'cost-effective use of healthcare resources'?

@en

P2093

David Gurwitz

http://www.w3.org/2001/XMLSchema#string

Dolores Ibarreta

http://www.w3.org/2001/XMLSchema#string

Kathryn A Phillips

http://www.w3.org/2001/XMLSchema#string

P2860

TPMT testing in rheumatology: any better than routine monitoring?

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?

Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions.

Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.

Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects.

Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.

Fatal myelotoxicity after azathioprine treatment.

P304

103-113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/17410541.6.1.103

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

William G. Newman

Katherine Payne

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29783387

http://www.w3.org/2001/XMLSchema#string